ArticleJournal of biological engineering2026
Stem cell research and regenerative medicine: meeting report from the Royan International Stem Cell Congress 2025.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 21st Royan International Stem Cell Congress (3-5 September 2025, Tehran, Iran) convened the global stem cell community to assess the accelerating translation of regenerative medicine from bench to bedside. Over three days, 10 thematic sessions, spanning pluripotency, cancer, organoid technology, molecular biomedicine, artificial intelligence (AI), bioengineering, and clinical translation, provided a comprehensive overview of a field undergoing increasing integration. Key presentations reported recent progress in several areas: the generation of primate and human embryo models for developmental study; new strategies in cross-species reprogramming and exosome-based therapeutics; and the application of AI for patient stratification, drug repurposing, and metabolic modeling. Concurrently, sessions on bioengineering showcased developments in next-generation biomaterials, non-viral gene delivery systems, and scalable microfluidic platforms aimed at enhancing therapeutic safety and manufacturability. The congress also featured critical discussions on regulatory frameworks, bioentrepreneurship, and the ecosystem required to support clinical adoption. Collectively, the meeting underscored a continuing shift toward a multidisciplinary paradigm in which foundational biology, emerging technology, and pragmatic translation converge to advance the development of safe, effective, and accessible stem cell-based therapies worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.